Bipinor 5 mg (Tablet)

Indications

• Hypertension
• Treatment of essential hypertension
• Chronic heart failure (CHF)
• Treatment of stable mild and moderate chronic heart failure in elderly patients.

Pharmacology

• Beta adrenergic receptor blocking agent
• Inhibition of beta1 and beta1 adrenergic receptors
• Lack of intrinsic sympathomimetic and membrane stabilizing activity
• Decreased heart rate
• Decreased myocardial contractility
• Diminution of tonic sympathetic outflow to the periphery from cerebral vasomotor centers
• Suppression of renin activity
• Vasodilation and decreased peripheral vascular resistance
• Metabolized by multiple routes including glucuronidation and hydroxylation by CYP2D6
• Mean peak plasma concentrations occur approximately 1.5 to 4 hours post-dosing
• Predominantly metabolized via direct glucuronidation of parent and to a lesser extent via N-dealkylation and oxidation via cytochrome P450 2D6

Dosage & Administration

• Individualized dosing based on patient's needs
• Recommended starting dose of 5 mg once daily
• Dose can be increased at 2-week intervals up to 40 mg for patients requiring further reduction in blood pressure

Interaction

• Use with care when myocardial depressants or inhibitors of AV conduction are used concurrently
• Avoid combined use with other beta-blockers
• Caution when co-administered with CYP2D6 inhibitors (quinidine, propafenone, fluoxetine, paroxetine, etc.)

Contraindications

• Severe bradycardia
• Heart block greater than first degree
• Cardiogenic shock
• Decompensated cardiac failure
• Sick sinus syndrome (without a permanent pacemaker in place)
• Severe hepatic impairment (Child-Pugh >B)
• Hypersensitivity to any component of this product

Side Effects

• Headache
• Nausea
• Bradycardia

Precautions & Warnings

• Abrupt cessation of therapy
• Caution in patients with coronary artery disease
• Cautious administration in compensated congestive heart failure
• Not studied in patients with angina pectoris or recent Ml
• Avoid use in patients with bronchospastic diseases
• Closely monitor patients when using anesthetic agents which depress myocardial function
• Caution in patients subject to spontaneous hypoglycemia or diabetic patients receiving insulin or oral hypoglycemic agents
• Monitoring for signs of hyperthyroidism
• Exercise caution in patients with peripheral vascular disease
• Caution in patients treated concomitantly with non-dihydropyridine calcium channel blockers

Use in Special Populations

• Caution in patients with severe renal impairment
• Contraindicated in patients with severe hepatic impairment
• Potential for increased reactivity to allergen challenges in patients with a history of severe anaphylactic reactions

Therapeutic Class

• Beta-adrenoceptor blocking drugs
• Beta-blockers

Storage Conditions

• Keep below 30°C temperature
• Away from light & moisture
• Keep out of the reach of children

Related Brands

• Bipinor 2.5 mg (Tablet) - aci-limited